Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 18
Healthy volunteers: yes

Brief summary:
The purpose of this study is to measure how much of a new tablet formulation of lanabecestat gets into the blood stream and how long it takes the body to get rid of it, compared to the current tablet formulation of lanabecestat. The effect of a high fat meal on how quickly the body absorbs the new tablet formulation will also be evaluated. In addition any side effects of the study drug using both the new and current tablet formulations will be evaluated. The study will last about 22 days, with screening required within 30 days prior to the start of the study.

Detailed description:

Arms:
arm 1: Lanabecestat: 50 mg administered once PO in each of 3 treatment periods. arm 2: Lanabecestat: 50 mg administered once PO in each of 3 treatment periods. arm 3: Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.

Interventions: intervention 1: Lanabecestat
Intervention descriptions: intervention 1: Administered orally

Protocol document: